NCT07511543Not yet recruitingPhase 2
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy
A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular Thrombectomy
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
Endovascular thrombectomy (EVT) is a procedure that improves recovery for people who suffer from a stroke by removing blood clots from large blood vessels in the brain. However, even with this treatment, over half of the patients either pass away or are left with serious disabilities within three months. This is partly because, even in cases of a successful EVT, brain tissue damage continues to grow. Extent of brain damage is a major factor in how well a patient recovers. Studies in animals have shown that a drug called semaglutide might help protect the brain and improve recovery after a stroke. Semaglutide is currently used for the treatment of diabetes and obesity and is given as a weekly injection under the skin. The investigators are hoping to test whether giving semaglutide to stroke patients undergoing EVT can improve their recovery. A very large study at many hospitals is needed to answer this question. The investigators are starting with a smaller study to gain information on whether it is possible to perform a larger definitive one, and if so, how best to plan for it. In this first step we will study 100 patients with stroke who are scheduled for EVT in approximately 10 stroke centers across Canada. These patients will be randomly divided (like flipping a coin) into two groups: one will receive weekly semaglutide injections for 12 weeks, while the other will not receive the drug. The investigators will track how many patients agree to participate, how many stay in the study, and how well they follow the treatment plan. The investigators will also monitor the patients' recovery, overall health, and any side effects from the treatment. These results will provide important information to plan our larger study with the goal of reducing death rates and long-term disability in stroke patients undergoing EVT.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 31 Oct 2028
- Lead sponsor
- Population Health Research Institute
- Diseases
- Stroke
- NCT number
- NCT07511543
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 31 Oct 2026 to the primary completion date, 31 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of pancreatitis in the year prior to randomization or evidence of acute pancreatitis on randomization.
- Active treatment with an GLP-1RA prior to randomization.
Other illness
- Cancer, regionally advanced or metastatic, or for which treatment had been administered within 6 months from randomization, or hematological cancer that is not in complete remission.
- Any terminal medical condition with life expectancy of less than 3 months.
- Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to GLP-1 RAs.
Lab values
- Renal insufficiency (creatinine clearance \< 30mL/min).
Other
- Pregnancy or breast-feeding.
- Cirrhosis or severe hepatic dysfunction, characterized by jaundice, encephalopathy or coagulopathy.
- Active sepsis on randomization.
- Body mass index (BMI) less than 19.
- Refusal or inability to administer subcutaneous (SC) injections by the patient or a caregiver.
- Close affiliation with the investigational site.
Who the study is looking for
- Age 18 years or above on the date of randomization.
- EVT for an LVO in the anterior circulation, defined as the intracranial segment of the internal carotid artery (ICA) and/or the M1 or proximal M2 segment of the middle cerebral artery (MCA).
- National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points at the time of randomization.
- Pre-stroke modified Rankin Scale (mRS) 0 or 1.
- Ability to randomize within 6 hours from the end of EVT.
- Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.